Shortly after leaving the Merck pharmaceutical group, where he was replaced by Spaniard Belén Garijo at the beginning of the month, Stefan Oschmann joins the supervisory board of AiCuris. As the Düsseldorf-based company announced at the end of May, the former Merck CEO is joining the supervisory board and taking over as chairman. He thus replaces venture capital investor Helmut Jeggle, who had headed the supervisory board on an interim basis and now acts as deputy chairman. In addition to Jeggle and Marett, BionTech manager Sean Marett and founder Helga Rübsamen-Schaeff are two other industry experts on the board.
“Visionary from the research-based economy”
AiCuris AG, whose main investors are Andreas and Thomas Strüngmann, develops drugs against infectious diseases. The company was founded in 2006 as a spin-off from Bayer Healthcare. With Stefan Oschmann, the company has gained “a visionary from the research-based economy”, commented CEO Holger Zimmermann on the new addition. This is not the first supervisory board position for the ex-Merck boss: Oschmann already serves as chief controller of the Belgian biotech and pharmaceutical company UCB and oversees the scientific publisher Springer Nature.